Elsevier

Contraception

Volume 95, Issue 3, March 2017, Pages 223-226
Contraception

Commentary
Tubal contraception and ovarian cancer risk: a global view,☆☆

https://doi.org/10.1016/j.contraception.2016.09.004Get rights and content

Section snippets

Acknowledgments

The views expressed in this commentary do not necessarily reflect those of FHI 360, Virginia Commonwealth University, Brigham and Women's Hospital, Harvard University or the funding agencies.

First page preview

First page preview
Click to open first page preview

References (34)

  • National Academies of Sciences, Engineering, and Medicine

    Ovarian Cancers: Evolving Paradigms in Research and Care

    (2016)
  • D.W. Kindelberger et al.

    Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship

    Am J Surg Pathol

    (2007)
  • A.A. Tone et al.

    The role of the fallopian tube in ovarian cancer

    Clin Adv Hematol Oncol

    (2012)
  • S.M. King et al.

    The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer

    Endocr Relat Cancer

    (2011)
  • H.A. Risch et al.

    Pelvic inflammatory disease and the risk of epithelial ovarian cancer

    Cancer Epidemiol Biomarkers Prev

    (1995)
  • J.D. Seidman et al.

    Salpingitis, salpingoliths, and serous tumors of the ovaries: is there a connection?

    Int J Gynecol Pathol

    (2002)
  • R.B. Ness et al.

    Possible role of ovarian epithelial inflammation in ovarian cancer

    J Natl Cancer Inst

    (1999)
  • Funding: RLC and GSK are supported by grants from the Bill & Melinda Gates Foundation and a cooperative agreement from the United States Agency for International Development (USAID).

    ☆☆

    Conflicts of Interest: None.

    View full text